The Advisory and Board Member Team at Cellanyx provides strategic guidance, governance, and expert insights to drive the development and commercialization of proprietary live tumor cell phenotypic biomarker tests. This team oversees company direction, advises on critical decisions, and ensures alignment with industry best practices to improve cancer risk-stratification and inform clinical decision-making.